Jesper Hoeiland to step down as President and Chief Executive Officer in order to return to
Jesper will serve as a Senior Advisor to the Company to help facilitate a smooth transition
Kelly Martin has been appointed President and Chief Executive Officer
“On behalf of the Board and all Radius employees, I would like to extend our sincere thanks to Jesper for his many contributions to the Company over the past several years. His leadership helped establish TYMLOS as the leading anabolic therapy in the US osteoporosis market in a little over two years,” stated
“It has been a tremendous personal and professional privilege to serve as the CEO of Radius,” stated Jesper Hoeiland. “I am proud of the Company’s many accomplishments during my tenure and even more so the people that made it happen. I remain enthusiastic about the Company’s prospects and its ability to extend and expand its leadership in the years ahead with the advancement of its pipeline and, in particular, the progress being made with the abaloparatide-patch.”
Jesper commented further that, “after nearly 25 years away from ‘home’, my wife and I have decided to return to
Kelly Martin will assume the role of CEO and President of Radius with immediate effect. “The Board is delighted that Kelly is joining Radius. We look forward to working with him – and the entire Radius team – in moving the Company forward,” stated
Kelly Martin is a globally experienced executive with a strong track record of success. He spent 22 years at Merrill Lynch and was a member of the Executive Management Committee. Following that, he spent 12 plus years as the CEO of
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations regarding achieving profitability and the timing thereof; our expectations regarding the advancement of our pipeline; and our expectations in connection with the transition of our CEO and President.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important risks and uncertainties discussed in our filings with the
Investor & Media Relations Contact:
Source: Radius Health Inc.